Nuformix (NFX) Now Covered by Beaufort Securities

Analysts at Beaufort Securities assumed coverage on shares of Nuformix (LON:NFX) in a report issued on Friday. The firm set a “speculative buy” rating and a GBX 5 ($0.07) price target on the stock. Beaufort Securities’ price objective points to a potential upside of 25.00% from the stock’s previous close.

Shares of Nuformix (NFX) opened at GBX 4 ($0.05) on Friday. Nuformix has a fifty-two week low of GBX 1.75 ($0.02) and a fifty-two week high of GBX 4.70 ($0.06).

COPYRIGHT VIOLATION WARNING: “Nuformix (NFX) Now Covered by Beaufort Securities” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/17/nuformix-nfx-now-covered-by-beaufort-securities.html.

About Nuformix

Nuformix PLC, formerly Levrett PLC, is a United Kingdom-based pharmaceutical development company. The Company uses cocrystal technology to develop drugs with programs in oncology supportive care and fibrosis. It uses cocrystal technology to re-engineer the crystalline form of drugs. Its clinical pipeline includes NXP001 and NXP002.

Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit